Market Cap: $7.46B
AI
Axsome Therapeutics, Inc.
AXSM
NASDAQ (NASDAQ Global Market)USD
Market Cap: $7.46B
Axsome Therapeutics secures a pivotal settlement in the patent litigation regarding its wakefulness drug SUNOSI, significantly enhancing its operational stability. The agreement permits five companies…
Axsome Therapeutics, a biopharmaceutical company focused on central nervous system (CNS) disorders, recently resolves significant litigation related to its wakefulness drug SUNOSI. This settlement per…
Axsome Therapeutics (Ticker: AXSM) is making strategic advancements in its product portfolio, particularly with the anticipated launch of Auvelity, a treatment aimed at agitation in Alzheimer's diseas…
Axsome Therapeutics (Ticker: AXSM) has achieved a significant milestone by receiving U.S. FDA approval for AUVELITY, which is now recognized as the first non-antipsychotic medication specifically targ…
Helus Pharma's Promising Psychedelic Therapy: A Step Forward in Mental Health Treatments Helus Pharma, a clinical-stage pharmaceutical company, achieves a groundbreaking milestone with its positive ou…
Psychedelic Breakthrough: Helus Pharma Advances Mental Health Treatments Helus Pharma, a clinical-stage therapeutic company, reaches a crucial milestone by achieving positive Phase 3 results for its p…
Axsome Therapeutics: Navigating Divergent Analyst Perspectives on Company Outlook In the fast-evolving biotech landscape, Axsome Therapeutics (NASDAQ: AXSM) stands out as a focal point of varied analy…
Axsome Therapeutics: A Complex Landscape of Analyst Perspectives Axsome Therapeutics, a prominent player in the biopharmaceutical industry focusing on innovative treatments for central nervous system…
Axsome Therapeutics Prepares for Critical Earnings Report As Axsome Therapeutics approaches the release of its quarterly earnings on February 23, 2026, key stakeholders focus on critical indicators th…
New trial result redefines agitation-in‑Alzheimer’s treatment debate NMRA-511 demonstrates a clinically meaningful effect size in people with agitation related to Alzheimer’s disease, a result that re…
Axsome Therapeutics Advances Alzheimer's Care with FDA Acceptance of AXS-05 NDA On Wednesday, Axsome Therapeutics Inc. announces a pivotal development in its efforts to address the challenges of Alzhe…
Axsome Therapeutics Advances Alzheimer's Treatment with FDA Acceptance In a significant development for the treatment of Alzheimer's disease, Axsome Therapeutics Inc. announces that the U.S. Food and…
Jazz Pharmaceuticals Prepares for Key Earnings Announcement Amid Product Pipeline Developments As Jazz Pharmaceuticals approaches its upcoming quarterly earnings announcement on November 5, 2025, the…
Axsome Therapeutics: Pioneering Innovations in Neurology Amidst Competitive Landscape Axsome Therapeutics stands at the forefront of advancing treatment options in the neurology sector, particularly w…
Axsome Therapeutics Navigates Competitive Landscape Amid Earnings Reports Axsome Therapeutics, a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) d…
Axsome Therapeutics Prepares for Crucial Earnings Report Amid Drug Development Focus Axsome Therapeutics is set to unveil its latest quarterly earnings report on November 3, 2025, a moment of consider…
Axsome Therapeutics Prepares for Critical Earnings Report Amid Drug Development Focus Axsome Therapeutics gears up for its upcoming quarterly earnings report, scheduled for November 3, 2025. This repo…
Axsome Therapeutics: Navigating Opportunities and Challenges in CNS Therapy Development Axsome Therapeutics, a biopharmaceutical company focusing on innovative therapies for central nervous system (CN…
Axsome Therapeutics Faces Divergent Analyst Opinions Amid Promising Clinical Developments Axsome Therapeutics, a biopharmaceutical company focused on developing innovative therapies for central nervou…
Axsome Therapeutics Navigates a Landscape of Mixed Analyst Opinions In the biopharmaceutical sector, Axsome Therapeutics (AXSM) finds itself at a critical juncture, as analysts present a spectrum of o…
New Hope for Fibromyalgia Patients: Tonix Pharmaceuticals Receives FDA Approval for TNXP Tonmya In a notable development for the treatment of chronic pain, the U.S. Food and Drug Administration (FDA)…
Tonix Pharmaceuticals Advances Fibromyalgia Treatment with FDA Approval of TNXP Tonmya In a significant development for the management of fibromyalgia, Tonix Pharmaceuticals Holding Corp. receives FDA…
Tonix Pharmaceuticals Secures FDA Approval for Fibromyalgia Treatment: A New Era in Pain Management In a significant development for chronic pain management, Tonix Pharmaceuticals Holding Corp. receiv…
Axsome Therapeutics Reports Strong Second Quarter Performance Amidst Strategic Growth Initiatives Axsome Therapeutics, Inc. (AXSM) announces its second-quarter financial results, revealing a notable p…
Axsome Therapeutics Prepares for Key Earnings Announcement Amidst Promising Developments Axsome Therapeutics, a leading biopharmaceutical company specializing in innovative therapies for central nervo…